



## Referenzliste | liste de référence Newsletter 01/2024

- [1] Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. *Lancet*. 2022 Sep 3;400(10354):769-786.
- [2] Buschulte K, Cottin V, Wijsenbeek M, et al. The world of rare interstitial lung diseases. *Eur Respir Rev*. 2023 Mar 31;32(167).
- [3] American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J Respir Crit Care Med*. 2002 Jan 15;165(2):277-304.
- [4] Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med*. 2013 Sep 15;188(6):733-48.
- [5] Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med*. 2011 Mar 15;183(6):788-824.
- [6] Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *Lancet Respir Med*. 2018 Feb;6(2):138-153.
- [7] Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2018 Sep 1;198(5):e44-e68.
- [8] Raghu G, Rochweg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2015 Jul 15;192(2):e3-19.
- [9] Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2022 May 1;205(9):e18-e47.
- [10] Rajan SK, Cottin V, Dhar R, et al. Progressive pulmonary fibrosis: an expert group consensus statement. *Eur Respir J*. 2023 Mar;61(3).
- [11] Collard HR, Ryerson CJ, Corte TJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am J Respir Crit Care Med*. 2016 Aug 1;194(3):265-75.
- [12] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J*. 2023 Jan;61(1):2200879.
- [13] Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J*. 2019 Jan;53(1):1801913.
- [14] Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. *Lancet Respir Med*. 2016 Apr;4(4):306-22.
- [15] Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. *Chest*. 2006 Mar;129(3):746-52.
- [16] Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. *Chest*. 2005 Oct;128(4):2393-9.
- [17] Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2021 Nov;40(11):1349-1379.



- [18] Behr J, Nathan SD, Wuyts WA, et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. *Lancet Respir Med*. 2021 Jan;9(1):85-95.
- [19] Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. *Am J Respir Crit Care Med*. 2014 Jul 15;190(2):208-17.
- [20] Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. *Chest*. 2013 Jun;143(6):1699-1708.
- [21] King TE, Jr., Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2011 Jul 1;184(1):92-9.
- [22] Kolb M, Raghu G, Wells AU, et al. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med*. 2018 Nov 1;379(18):1722-1731.
- [23] Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. *Lancet Respir Med*. 2019 Sep;7(9):780-790.
- [24] Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. *Ann Intern Med*. 2013 May 7;158(9):641-9.
- [25] Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. *Eur Respir J*. 2013 Dec;42(6):1622-32.
- [26] Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. *N Engl J Med*. 2021 Jan 28;384(4):325-334.
- [27] Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. *Lancet Respir Med*. 2021 Nov;9(11):1266-1274.
- [28] Nathan SD, Tapson VF, Elwing J, et al. Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. *Am J Respir Crit Care Med*. 2022 Jan 15;205(2):198-207.
- [29] Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. *Eur Respir J*. 2019 Jan;53(1):1801904.
- [30] Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. *Am J Respir Crit Care Med*. 2004 Aug 15;170(4):360-5.
- [31] Sonti R, Gersten RA, Barnett S, et al. Multimodal noninvasive prediction of pulmonary hypertension in IPF. *Clin Respir J*. 2019 Sep;13(9):567-573.
- [32] Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. *Chest*. 2007 Mar;131(3):657-663.
- [33] Olsson KM, Corte TJ, Kamp JC, et al. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management. *Lancet Respir Med*. 2023 Sep;11(9):820-835.
- [34] Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med*. 2003 Mar 1;167(5):735-40.
- [35] Keir GJ, Wort SJ, Kokosi M, et al. Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. *Respirology*. 2018 Jul;23(7):687-694.



- [36] Swift AJ, Dwivedi K, Johns C, et al. Diagnostic accuracy of CT pulmonary angiography in suspected pulmonary hypertension. *Eur Radiol.* 2020 Sep;30(9):4918-4929.
- [37] Truong QA, Bhatia HS, Szymonifka J, et al. A four-tier classification system of pulmonary artery metrics on computed tomography for the diagnosis and prognosis of pulmonary hypertension. *J Cardiovasc Comput Tomogr.* 2018 Jan-Feb;12(1):60-66.
- [38] Devaraj A, Wells AU, Meister MG, et al. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. *Radiology.* 2008 Dec;249(3):1042-9.
- [39] Rahaghi FF, Kolaitis NA, Adegunsoye A, et al. Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study. *Chest.* 2022 Jul;162(1):145-155.
- [40] Ryerson CJ, Corte TJ, Myers JL, et al. A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. *Eur Respir J.* 2021 Dec;58(6).
- [41] Shiolen AM, Ruopp NF. Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials. *Clin Chest Med.* 2021 Mar;42(1):59-70.
- [42] Dawes TJW, McCabe C, Dimopoulos K, et al. Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. *Respirology.* 2023 Mar;28(3):262-272.
- [43] Nathan SD, Behr J, Cottin V, et al. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. *BMJ Open Respir Res.* 2022 Jul;9(1).
- [44] Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. *Eur Respir J.* 2023 Jun;61(6).
- [45] Lee C, Hamlyn J, Porcelli J, et al. Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3). *Respir Med.* 2022 May;196:106806.
- [46] Spikes LA, Bajwa AA, Burger CD, et al. BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI in patients with pulmonary arterial hypertension. *Pulm Circ.* 2022 Apr;12(2):e12063.
- [47] Ismat FA, Usansky HH, Villa R, et al. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study. *Adv Ther.* 2022 Nov;39(11):5144-5157.
- [48] Johnson SW, Finlay L, Mathai SC, et al. Real-world use of inhaled treprostinil for lung disease-pulmonary hypertension: A protocol for patient evaluation and prescribing. *Pulm Circ.* 2022 Jul;12(3):e12126.